Phase 1/2Data readout

CT2000 (NaV1.7 Inhibitor)

Dry Eye Disease With Chronic Eye Pain

PTHSPelthos Therapeutics

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: CT2000 (NaV1.7 Inhibitor)
Development stage: Phase 1/2
Event type: Data readout
Indication: Dry Eye Disease With Chronic Eye Pain

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for CT2000 (NaV1.7 Inhibitor) in Dry Eye Disease With Chronic Eye Pain. The expected timing is based on the latest available company guidance and may change.

Development notes

05/14/26:- PR No update. 08/13/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided